Synthego

Overview
News
Human Gene Editing?
Product stageSegments
Growth
?
Gene editing support services
?

Synthego develops CRISPR-based tools, such as CRISPR designing, analysis, and screening libraries, to support pharmaceutical and biotech companies as well as academia to accelerate the R&D of novel gene editing therapeutics for diseases like cancer. It also manufactures different types of synthetic ribonucleic acid (RNA), specific for different CRISPR nucleases, within days, which otherwise takes weeks. 

Founded in 2012, Synthego offers two main platforms: “HALO,” a CRISPR design tool for knockouts, and its recently released high throughput cell engineering platform “Eclipse,” which enables the development of highly predictable CRISPR-engineered cells. The company possesses libraries of over 120,000 genomes and over 8,300 species and offers a variety of bioinformatic tools and services including a CRISPR data analysis software Inference of CRISPR Edits (ICE) that enables interpretation of gene editing results. In May 2021, it received ISO 9001:2015 certification for its good manufacturing practices (GMP)-grade single guided RNA (sgRNA) manufacturing processes. 

Key customers and partnerships

Synthego’s customer base consists of over 17,000 CRISPR researchers customers across 45 countries, which reportedly includes eight of the top ten big pharma companies in the world. The company has contributed to over 1,000 peer-reviewed journals and has secured various partnerships with government bodies including the National Institutes of Health (NIH) to develop stem cell models of Alzheimer’s disease. In August 2023 , the company partnered with precision cell programming company bit.bio to explore synthetic circuitry implementation in cells for therapeutic purposes.

Funding and financials

In its latest Series E funding round in February 2022, Synthego raised USD 200 million, bringing its total funds raised to USD 459.7 million. The company intended to use the funds to further develop its platforms with advanced capabilities such as CRISPROff—a light-based system for enhanced precision in gene editing.

HQ location:
3696 Haven Avenue Suite A Redwood City CA USA
Founded year:
2012
Employees:
251-500
IPO status:
Private
Total funding:
USD 459.7 mn
Last Funding:
USD 200.0 mn (Series E; Feb 2022)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.